# Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients

> **NCT01105481** · PHASE4 · COMPLETED · sponsor: **National Health Research Institutes, Taiwan** · enrollment: 273 (actual)

## Conditions studied

- Treatment-resistant Schizophrenia

## Interventions

- **DRUG:** Amisulpride add-on
- **DRUG:** Placebo add-on

## Key facts

- **NCT ID:** NCT01105481
- **Lead sponsor:** National Health Research Institutes, Taiwan
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2008-03
- **Final completion:** 2008-06
- **Target enrollment:** 273 (ACTUAL)
- **Last updated:** 2010-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01105481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01105481, "Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01105481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*